Health-related quality of life with adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): secondary outcomes of a multinational, randomised, double-blind, phase 3 trial-Reference-Cited by-同舟云学术

Health-related quality of life with adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): secondary outcomes of a multinational, randomised, double-blind, phase 3 trial

Published:2017-03 Issue:3 Volume:18 Page:393-403
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Coens Corneel,Suciu Stefan,Chiarion-Sileni Vanna,Grob Jean-Jacques,Dummer Reinhard,Wolchok Jedd D,Schmidt Henrik,Hamid Omid,Robert Caroline,Ascierto Paolo A,Richards Jon M,Lebbé Celeste,Ferraresi Virginia,Smylie Michael,Weber Jeffrey S,Maio Michele,Bottomley Andrew,Kotapati Srividya,de Pril Veerle,Testori Alessandro,Eggermont Alexander M M

Publisher

Elsevier BV

Subject

Oncology

Reference29 articles.

1. Cutaneous melanoma;Eggermont;Lancet,2014

2. Final version of 2009 AJCC melanoma staging and classification;Balch;J Clin Oncol,2009

3. Multivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases;Balch;J Clin Oncol,2010

4. Prognosis in patients with sentinel node-positive melanoma is accurately defined by the combined Rotterdam tumor load and Dewar topography criteria;van der Ploeg;J Clin Oncol,2011

5. The prognostic significance of sentinel node tumour burden in melanoma patients: an international, multicenter study of 1539 sentinel node-positive melanoma patients;van der Ploeg;Eur J Cancer,2014

Cited by 96 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Measuring success of adjuvant treatment for patients with melanoma;The Lancet Oncology;2024-09

2. Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): long-term, health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial;The Lancet Oncology;2024-09

3. lnsights into Adjuvant Systemic Treatment Selection for Patients with Stage III Melanoma: Data from the Dutch Cancer Registry;Targeted Oncology;2024-08-24

4. Understanding quality of life issues in patients with advanced melanoma: Phase 1 and 2 in the development of the EORTC advanced melanoma module;European Journal of Cancer;2024-08

5. Immunotherapy of Human Melanoma: Past, Present, Future;Current Medicinal Chemistry;2024-03-06